InvestorWire NewsRoom


Nemaura Medical Inc. (NASDAQ: NMRD) Releases Q2-2021 Results, Signs Global Commercial Contract with MySugarWatch DuoPack Limited
December 2, 2021

Nemaura Medical Inc. (NASDAQ: NMRD) Releases Q2-2021 Results, Signs Global Commercial Contract with MySugarWatch DuoPack Limited

  • NMRD releases fiscal Q2-2021 results, provides business update
  • Highlights include pending revenue recognition, global commercial contract with MySugarWatch DuoPack Limited, appointment of Dr. Osama Hamdy to advisory board
  • Company operates at intersection of $59 billion Type 2 diabetes market, $50+ billion pre-diabetic market, $60 billion wearable weight loss and wellness applications sector 

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, recently released its fiscal Q2-2021 results and provided a business update (

Financial highlights from the announcement included $26.8M cash on hand, and receipt of an initial $513,000 as deposit payment from its UK licensee as partial payment for an order of 200,000 sensors and associated devices. Management expects to convert this and future invoiced payments to revenue once the Company begins delivering the final product to its licensee, scheduled to start during Q4-2021. 

NMRD is currently commercializing its sugarBEAT(R) and proBEAT(TM) non-invasive and flexible continuous glucose monitors that provide actionable insights from real-time glucose monitoring to help diabetic and pre-diabetic people better manage, reverse, and prevent the onset of diabetes. The Company recently welcomed Dr. Osama Hamdy, M.D., Ph.D., to its advisory board, who will take part and advise on diabetes and metabolic health studies using Nemaura’s glucose monitoring technology. Dr. Hamdy is a senior endocrinologist and medical director, Obesity Clinic Program at the Joslin Diabetes Center and an associate professor of medicine at Harvard Medical School. Dr. Hamdy is a world-renowned thought leader in the field of obesity management in diabetes, medical nutrition and digital health.

NMRD also announced the signing of a global commercial contract with MySugarWatch DuoPack Limited to provide continuous glucose monitors and sensors as Duo-Packs, to be sold with prescription-only medicines typically prescribed to people with Type 2 diabetes. “We continue to make progress in our commercializing efforts for sugarBEAT(R) in the UK and recognizing revenue from our licensee. We are also working closely with advisors to expand our footprint throughout the world to address the worldwide health crisis of diabetes using our skin-mounted needle-free CGM as an innovative solution for patients and consumers,” said Dr. Faz Chowdhury, CEO of Nemaura Medical. 

“Combined with our digital lifestyle management programs, we believe that our technology offering has the potential to be a key tool for the prevention and management of Type 2 diabetes. As we progress with our corporate, clinical, and regulatory milestones, we will provide future investor updates.”

Founded in 2011, Nemaura initially developed a single platform technology to measure blood markers at the skin’s surface. The Company has since evolved with the creation of wearable technologies and digital health care solutions at the intersection of three rapidly growing markets: the global Type 2 diabetes market expected to reach $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable weight loss and wellness applications sector, estimated to reach $60 billion by 2023 ( With obesity and diabetes as the two major drivers fueling the chronic disease epidemic, NMRD is committed to preventing, managing, and reversing these conditions by offering non-invasive, affordable, and flexible glucose monitoring solutions. 

For more information, visit the company websites at

NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Recent Articles

Release Categories

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).